IKT — Inhibikase Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-PagSeguro Digital, Finch Therapeutics, Mastercard
U.S. STOCKS ON THE MOVE-Inhibikase, Bed Bath & Beyond, Electronic Arts
Brief: Inhibikase Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Ikt-001Pro
Brief: Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2A '201' Clinical Trial Of Ikt-148009 To Treat Parkinson's Disease
Brief: Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Period Activity
Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Inc - On June 25, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Inhibikase Therapeutics Announces Advancement Of Ikt-148009 Phase 2 '201' Program Following FDA Review
Inhibikase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Inhibikase Therapeutics Reports Q1 2022 Results
Inhibikase Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Inhibikase Therapeutics Reports Full Year 2021 Financial Results
Inhibikase Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics To Present Phase 1/1B Clinical Data At The Upcoming Ad/Pd Alzheimer's & Parkinson's Diseases Conference
Brief: Inhibikase Therapeutics Files For Mixed Shelf Of Up To $100 Million - Filing
Brief: Fivet Investment Management Ltd Reports 6.03% Stake In Inhibikase Therapeutics
Brief: Inhibikase Therapeutics Reports Q3 Loss Per Share Of $0.18